Drug firms looking to ramp-up production with continuous processes must think beyond the reactor and ensure the technologies used downstream can also manage sustained 24/7 manufacturing. Continuous ...
Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...
Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results